MEIS1
Overview
MEIS1 is a TALE-class homeobox transcription factor that plays critical roles in hematopoiesis, neurogenesis, and limb development. It acts as a co-factor for HOXA and HOXB proteins and is involved in stem cell self-renewal programs. In cancer, MEIS1 over-expression has been implicated in leukemia and several solid tumors. In extra-cranial MRT, MEIS1 is among the most over-expressed genes in mRNA sub-group 2, which is characterized by cell adhesion/migration, WNT, and differentiation pathway activity.
Alterations observed in the corpus
- MEIS1 is among the most over-expressed genes in mRNA sub-group 2 of extra-cranial MRT (characterized by cell adhesion/migration, WNT signaling, and differentiation pathways); this sub-group parallels the AT/RT RTK subtype described previously PMID:26977886
Cancer types (linked)
- MRT (Malignant Rhabdoid Tumor): MEIS1 over-expression defines a transcriptional sub-group (mRNA sub-group 2) in 40-sample extra-cranial MRT cohort. PMID:26977886
Co-occurrence and mutual exclusivity
- MEIS1 over-expression co-occurs with WNT5A, PCDH18, and TCF21 over-expression in mRNA sub-group 2 MRT, distinct from BMP4/DLK1/MEOX2 over-expression in sub-group 1. PMID:26977886
Therapeutic relevance
- No therapeutic implications described in the corpus; MEIS1 over-expression is a molecular sub-group marker rather than an established therapeutic target in this study.
Open questions
- Whether MEIS1 over-expression in MRT sub-group 2 is mechanistically driven by SMARCB1 loss or reflects a distinct cell-of-origin and whether sub-group-specific therapeutic hypotheses can be developed remain open questions. PMID:26977886
Sources
This page was processed by crosslinker on 2026-05-14.